82.1 F
San Fernando
Thursday, Mar 28, 2024

Pfizer Approval Could Pave Way for MannKind

The Food and Drug Administration on Friday approved the first version of inhalable insulin called “Exubera,” which was developed by Pfizer Inc. along with Sanofi-Aventis and Nektar Therapeutics. MannKind Inc. is developing a similar product called Technosphere, and the approval of Exubera could make it easier for MannKind to move its version through the regulatory process in the coming months. Analysts have predicted that Exubera could eventually become a $1 billion-per-year product for Pfizer, which paid $1.3 billion to Sanofi-Aventis for worldwide rights to the product.

Featured Articles

Related Articles